Agios Pharmaceuticals Inc (NASDAQ:AGIO)

110.44
Delayed Data
As of Jul 02
 +2.69 / +2.50%
Today’s Change
33.01
Today|||52-Week Range
138.85
-1.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$4.1B

Company Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, or RGDs, which are a subset of rare genetic diseases. The company's products include IDH1 AND IDH2, PKR, II D-2 hydroxyglutaric aciduria, AG-221 and AG-120. Agios Pharmaceuticals was founded by Lewis Clayton Cantley, Tak W. Mak and Craig B. Thompson on August 7, 2007 and is headquartered in Cambridge, MA.

Contact Information

Agios Pharmaceuticals, Inc.
38 Sidney Street
Cambridge Massachusetts 02139-4169
P:(617) 649-8600
Investor Relations:
(617) 649-8608

Employees

Shareholders

Mutual fund holders50.12%
Individual stakeholders36.72%
Other institutional21.81%

Top Executives

David Paul SchenkeinPresident, Chief Executive Officer & Director
John Duncan HiggonsChief Operating Officer
Glenn GoddardSenior Vice President-Finance
Shin-San Michael SuSenior Vice President-Research & Development
Scott BillerChief Scientific Officer

To view my watchlist

Not a member yet?

Sign up now for a free account